94 related articles for article (PubMed ID: 3802028)
21. [Combined chemo- and hormone-therapy in advanced ovarian carcinoma--theoretical, experimental foundations and clinical results].
Sevelda P
Wien Klin Wochenschr Suppl; 1990; 183():3-29. PubMed ID: 2145702
[TBL] [Abstract][Full Text] [Related]
22. [Therapeutic results of malignant ovarian tumor].
Fukazawa I; Masubuchi S; Okajima H; Fukuda K; Hayashi K; Yokosuka K; Miyata R; Masubuchi K
Gan No Rinsho; 1984 Jun; 30(7):819-26. PubMed ID: 6431145
[TBL] [Abstract][Full Text] [Related]
23. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.
Crump M; Smith AM; Brandwein J; Couture F; Sherret H; Sutton DM; Scott JG; McCrae J; Murray C; Pantalony D
J Clin Oncol; 1993 Apr; 11(4):704-11. PubMed ID: 8478664
[TBL] [Abstract][Full Text] [Related]
24. Taxane/platinum/anthracycline combination therapy in advanced epithelial ovarian cancer.
Hill M; Macfarlane V; Moore J; Gore ME
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-34-S2-37. PubMed ID: 9045334
[TBL] [Abstract][Full Text] [Related]
25. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
26. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
Young RC; Chabner BA; Hubbard SP; Fisher RI; Bender RA; Anderson T; Simon RM; Canellos GP; DeVita VT
N Engl J Med; 1978 Dec; 299(23):1261-6. PubMed ID: 101843
[TBL] [Abstract][Full Text] [Related]
27. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome.
Safra T; Groshen S; Jeffers S; Tsao-Wei DD; Zhou L; Muderspach L; Roman L; Morrow CP; Burnett A; Muggia FM
Cancer; 2001 Jan; 91(1):90-100. PubMed ID: 11148564
[TBL] [Abstract][Full Text] [Related]
28. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
[TBL] [Abstract][Full Text] [Related]
29. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results.
Legros M; Dauplat J; Fleury J; Cure H; Suzanne F; Chassagne J; Bay JO; Sol C; Canis M; Condat P; Choufi B; Tavernier F; Glenat C; Chollet P; Plagne R
J Clin Oncol; 1997 Apr; 15(4):1302-8. PubMed ID: 9193321
[TBL] [Abstract][Full Text] [Related]
30. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma.
Weaver CH; Greco FA; Hainsworth JD; Zhen B; Baldwin P; Wittlin F; Lewis M; West WH; Schwartzberg L; Buckner CD
Bone Marrow Transplant; 1997 Nov; 20(10):847-53. PubMed ID: 9404925
[TBL] [Abstract][Full Text] [Related]
31. Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer.
Miller AB; Klaassen DJ; Boyes DA; Dodds DJ; Gerulath A; Kirk ME; Levitt M; Pearson JG; Wall C
Can Med Assoc J; 1980 Sep; 123(5):365-71. PubMed ID: 7020903
[TBL] [Abstract][Full Text] [Related]
32. Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.
Goa KL; Faulds D
Drugs Aging; 1994 Sep; 5(3):200-34. PubMed ID: 7803948
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy in ovarian carcinoma recurrent after radiation therapy.
Lele SB; Piver MS; Barlow JJ
Obstet Gynecol; 1978 Jan; 51(1):101-4. PubMed ID: 619324
[TBL] [Abstract][Full Text] [Related]
34. [Intermittent administration of the combination chemotherapy with cis-platin, adriamycin and cyclophosphamide (cyclic-PAC chemotherapy) for the ovarian cancers].
Inoue M; Nakanishi K; Nakazawa A; Ogawa H; Shimizu H; Saitoh J; Tanaka Y; Ueda G; Tanizawa O
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):347-52. PubMed ID: 2358719
[TBL] [Abstract][Full Text] [Related]
35. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
36. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
[TBL] [Abstract][Full Text] [Related]
37. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study.
Cooper MR; McIntyre OR; Propert KJ; Kochwa S; Anderson K; Coleman M; Kyle RA; Prager D; Rafla S; Zimmer B
J Clin Oncol; 1986 Sep; 4(9):1331-9. PubMed ID: 3528403
[TBL] [Abstract][Full Text] [Related]
38. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
39. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?
Kim JJ; Park JY; Kim DY; Kim JH; Kim YM; Nam JH; Kim YT
Acta Obstet Gynecol Scand; 2010 May; 89(5):623-8. PubMed ID: 20423275
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy of ovarian cancer.
Ozols RF; Young RC
Semin Oncol; 1984 Sep; 11(3):251-63. PubMed ID: 6435250
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
